Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. operates as a global diversified pharmaceutical company with business segments spanning gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and eye health. News related to Bausch Health may cover developments across any of these therapeutic areas, including product approvals, clinical trial results, regulatory actions, and commercial launches. The company's Salix business unit focuses on gastroenterology products, with particular emphasis on treatments for hepatic encephalopathy, irritable bowel syndrome, and other gastrointestinal conditions.
Corporate news may include updates on the company's debt management strategies, as Bausch Health has historically carried significant debt obligations stemming from acquisitions. Financial reporting typically addresses performance across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Bausch + Lomb eye health business represents a substantial portion of company operations and may generate independent news flow regarding vision care products, contact lenses, ophthalmic pharmaceuticals, and surgical equipment.
Dermatology news through the Ortho Dermatologics business may cover new acne treatments, psoriasis therapies, and other prescription dermatology products. Aesthetic medicine developments from Solta Medical often involve non-invasive cosmetic treatment technologies. Strategic acquisitions represent a key component of Bausch Health's growth strategy, with the company periodically acquiring businesses with complementary products in core therapeutic areas. Patent litigation and intellectual property matters frequently impact pharmaceutical companies, and Bausch Health may face generic competition for key products as patents expire.
Regulatory filings, including SEC reports, clinical trial registrations, and FDA submissions, provide transparency into company operations and pipeline developments. Investors monitor revenue trends across business segments, particularly the gastroenterology franchise which includes high-value products. Generic pharmaceutical competition, international market performance, and research and development progress all contribute to the ongoing narrative around this diversified pharmaceutical enterprise.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its second-quarter financial results on August 9, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow, providing insights into the company's performance and business updates. Interested parties can access the materials through the Investor Relations section of Bausch Health's website. The company is focused on improving lives through its diverse portfolio in various health sectors, including gastroenterology and dermatology.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has appointed Thomas W. Ross, Sr. as the new chair of the Board of Directors following the resignation of Joseph C. Papa. Mr. Papa remains CEO until a successor is found. The Board is actively searching for a new CEO while affirming the company's full-year guidance for 2022, initially announced on June 8. The company aims to complete its spinoff from Bausch Health (NYSE/TSX: BHC) in 2023, contingent on various approvals and market conditions, with no reported disagreements leading to Mr. Papa's departure.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and Salix Pharmaceuticals announced the winners of the 2022 Salix Gastrointestinal Health Scholars Program, awarding $10,000 each to 10 students living with gastrointestinal diseases. This marks the third consecutive year of the program which received over 150 applications. The scholarship aims to assist students in their academic pursuits amid health challenges. The recipients span undergraduate and graduate categories, showcasing the company's commitment to supporting education for those impacted by GI conditions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the results of its 2022 annual meeting of shareholders held on June 21, 2022. All 12 nominated directors were elected, with Thomas J. Appio as CEO expressing gratitude towards former Board member Joseph C. Papa who resigned. John A. Paulson fills the vacancy and will serve as Board Chair. Shareholders approved executive compensation, amendments to the 2014 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent auditor until the 2023 meeting. Full voting results will be reported on Form 8-K.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced its presentation during the Annual Meeting of Shareholders held on June 21, 2022. The presentation highlights the company's diversified pharmaceutical operations, focusing on improving health outcomes through various products in gastroenterology, neurology, and eye health, primarily via its ownership of Bausch + Lomb. The company has also filed a Form 8-K detailing this presentation, available on its Investor Relations page, reinforcing its commitment to advancing global health.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals, will present new data on XIFAXAN® (rifaximin) at the European Association for the Study of the Liver's International Liver Congress™ 2022 in London from June 22-26, 2022. The research focuses on identifying factors precipitating overt hepatic encephalopathy (OHE) and aims to improve management strategies, reducing hospitalization risks. Salix, dedicated to addressing liver disease, emphasizes its role in enhancing patient care through research and development.
Bausch Health Companies (NYSE/TSX: BHC) announced it is suspending the IPO plans for its Solta Medical business due to challenging market conditions. Solta, a leader in medical aesthetics, offers advanced skin rejuvenation and body contouring solutions. The company aims to focus on driving Solta's revenue and operational milestones while retaining it within the Bausch Health portfolio to aid in deleveraging its balance sheet. CEO Thomas J. Appio expressed confidence in Solta's growth and market potential.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that it will present seven research posters for its products XIFAXAN®, TRULANCE®, and PLENVU® at Digestive Disease Week 2022 from May 21-24, 2022, in San Diego, California. The posters highlight significant findings, such as the efficacy of XIFAXAN in managing hepatic encephalopathy and IBS-D, TRULANCE's rapid response in treating IBS-C, and PLENVU’s high-quality bowel cleansing for colonoscopy preparations. The research results will be publicly accessible on DDW's ePoster website starting May 21, 2022.
KBRA has published its First-Quarter 2022 U.S. Bank Compendium, offering insights into the banking sector's performance. The report highlights the impact of inflation on vehicle prices and auto loan exposures within the KBRA-rated banks. It includes summaries of 1Q22 results for publicly traded U.S. banks, focusing on key performance metrics and credit ratios. Additionally, the Compendium features the top 10 low-cost deposit franchises and a detailed supplement of 171 debt issues rated by KBRA.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its participation in investor conferences, including the Goldman Sachs Leveraged Finance and Credit Conference on May 12, 2022, and the Barclays High Yield Bond & Syndicated Loan Conference on May 24, 2022. Key executives such as Tom Vadaketh and Christina Cheng will represent the company. Live webcasts of these events will be accessible on the Investor Relations page of their website. Bausch Health focuses on enhancing global health through a diverse range of pharmaceutical products.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
